Ridaforolimus for patients with progressive or recurrent malignant glioma: A perisurgical, sequential, ascending-dose trial

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 4, 2012, Pages 849-860

  Reardon, David A ^a   Wen, Patrick Y ^b   Alfred Yung, W K ^c   Berk, Lori ^d   Narasimhan, Narayana ^d   Turner, Christopher D ^d   Clackson, Timothy ^d   Rivera, Victor M ^d   Vogelbaum, Michael A ^e  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d ARIAD PHARMACEUTICALS INC   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Immunohistochemistry; Malignant glioma; Mammalian target of rapamycin; Pharmacodynamics; Ridaforolimus

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; RIDAFOROLIMUS;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CANCER GRADING; CANCER GROWTH; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TREATMENT FAILURE; FATIGUE; FEMALE; FEVER; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPONATREMIA; IMMUNOHISTOCHEMISTRY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PAIN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN FUNCTION; RASH; RECURRENT CANCER; SIDE EFFECT; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; COHORT STUDIES; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; SIROLIMUS;

EID: 84859790518     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1773-y     Document Type: Article

References (38)

1. American Cancer Society (2010) Cancer facts & figures 2010. American Cancer Society, Atlanta
2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97-109 (Pubitemid 47103521)
3. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Available at http://www.nccn.org. Accessed July 07, 2010
4. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics 2010. CA Cancer J Clin 60(5):277-300
5. Omuro AM, Faivre S, Raymond E (2007) Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther 6(7):1909-1919 (Pubitemid 47052481)
6. Dancey J (2010) mTOR signaling and drug development in cancer. Nat Rev Clin Oncol 7(4):209-219
7. Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, Inge L, Smith BL, Sawyers CL, Mischel PS (2003) Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 63(11):2742-2746 (Pubitemid 36667143)
8. Abounader R (2009) Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy. Expert Rev Anticancer Ther 9(2):235-245
9. Annovazzi L, Mellai M, Caldera V, Valente G, Tessitore L, Schiffer D (2009) mTOR, S6 and AKT expression in relation to proliferation and apoptosis/autophagy in glioma. Anticancer Res 29(8):3087-3094
10. Ermoian RP, Kaprealian T, Lamborn KR, Yang X, Jelluma N, Arvold ND, Zeidman R, Berger MS, Stokoe D, Haas-Kogan DA (2009) Signal transduction molecules in gliomas of all grades. J Neurooncol 91(1):19-26
11. Yang J, Liao D, Wang Z, Liu F, Wu G (2011) Mammalian target of rapamycin signaling pathway contributes to glioma progression and patients' prognosis. J Surg Res 168(1):97-102
12. McBride SM, Perez DA, Polley MY, Vandenberg SR, Smith JS, Zheng S, Lamborn KR, Wiencke JK, Chang SM, Prados MD, Berger MS, Stokoe D, Haas-Kogan DA (2010) Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival. J Neurooncol 97(1):33-40
13. Clackson T, Metcalf CA, Rivera VM, Knowles HL, Tang H, Burns D et al (2003) Broad anti-tumor activity of AP23573, an mTOR inhibitor in clinical development. Proc Am Soc Clin Oncol 22:882
14. Squillace R, Miller D, Clapham D, Berk L, Ning Y, Wardwell S et al (2008) Anti-tumor activity of the mTOR inhibitor deforolimus (AP23573; MK-8669) in sarcoma and endometrial cancer models and exploration of molecular correlates of sensitivity. 99th AACR Annual Meeting 2008; Poster presentation (Abstract 1482)
15. Rivera VM, Squillace RM, Miller D, Berk L, Wardwell SD, Ning Y, Pollock R, Narasimhan NI, Iuliucci JD, Wang F, Clackson T (2011) Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens. Mol Cancer Ther 10(6):1059-1071
16. Mita MM, Mita AC, Chu QS, Rowinsky EK, Fetterly GJ, Goldston M, Patnaik A, Mathews L, Ricart AD, Mays T, Knowles H, Rivera VM, Kreisberg J, Bedrosian CL, Tolcher AW (2008) Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 26(3):361-367 (Pubitemid 351171685)
17. Mita MM, Britten CD, Poplin E, Tap WD, Carmona A, Yonemoto L et al (2008) Deforolimus trial 106- A Phase I trial evaluating 7 regimens of oral Deforolimus (AP23573, MK-8669). J Clin Oncol, ASCO Annual Meeting Proceedings 26 (May 20 Supplement)
18. Hartford CM, Desai AA, Janisch L, Karrison T, Rivera VM, Berk L, Loewy JW, Kindler H, Stadler WM, Knowles HL, Bedrosian C, Ratain MJ (2009) A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res 15(4):1428-1434
19. SP Chawla, Tolcher AW, Staddon AP, Schuetze SM, D'Amato GZ, Blay JY et al (2006) Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas. J Clin Oncol 24:9505
20. Chawla SP, Tolcher AW, Staddon AP, Schuetze SM, D'Amato GZ, Blay JY et al (2007) Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas: Update of phase II trial. J Clin Oncol 25:10076
21. Chawla SP, Blay J, Ray-Coquard IL, Le Cesne A, Staddon AP, Milhem MM, Penel N, Riedel RF, Nguyen BB, Cranmer LD, Reichardt P, Bompas E, Song Y, Lee R, Eid JE, Loewy J, Haluska FG, Dodion PF, Demetri GD (2011) Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). J Clin Oncol 29; Abstr 10005
22. Mita M, Sankhala K, Abdel-Karim I, Mita A, Giles F (2008) Deforolimus (AP23573) a novel mTOR inhibitor in clinical development. Expert Opin Investig Drugs 17(12):1947-1954
23. Sessa C, Tosi D, Vigano L, Albanell J, Hess D, Maur M, Cresta S, Locatelli A, Angst R, Rojo F, Coceani N, Rivera VM, Berk L, Haluska F, Gianni L (2009) Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel. Ann Oncol
24. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7):1277-1280 (Pubitemid 20195640)
25. Cancer Therapy Evaluation Program (2006) Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003; published August 9, 2006. Available at: http://ctep.cancer.gov. Accessed April 23, 2010
26. Kuhn JG, Chang SM, Wen PY, Cloughesy TF, Greenberg H, Schiff D, Conrad C, Fink KL, Robins HI, Mehta M, DeAngelis L, Raizer J, Hess K, Lamborn KR, Dancey J, Prados MD (2007) Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res 13(24):7401-7406
27. Duran I, Kortmansky J, Singh D, Hirte H, Kocha W, Goss G, Le L, Oza A, Nicklee T, Ho J, Birle D, Pond GR, Arboine D, Dancey J, Aviel-Ronen S, Tsao MS, Hedley D, Siu LL (2006) A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 95(9):1148-1154 (Pubitemid 44660065)
28. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Ramon y Cajal S, Jones S, Vidal L, Shand N, Macarulla T, Ramos FJ, Dimitrijevic S, Zoellner U, Tang P, Stumm M, Lane HA, Lebwohl D, Baselga J (2008) Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26(10):1603-1610
29. Wan X, Helman LJ (2007) The biology behind mTOR inhibition in sarcoma. Oncologist 12(8):1007-1018 (Pubitemid 47359144)
30. Martin KA, Rzucidlo EM, Merenick BL, Fingar DC, Brown DJ, Wagner RJ, Powell RJ (2004) The mTOR/p70 S6K1 pathway regulates vascular smooth muscle cell differentiation. Am J Physiol Cell Physiol 286(3):C507-C517 (Pubitemid 38292656)
31. Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW, Sonenberg N (2004) eIF4E-from translation to transformation. Oncogene 23(18):3172-3179
32. Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S, Mischel PS, MellinghoV IK, Sawyers CL (2008) Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 5(1):e8
33. Vogelbaum MA, Palomo J, Agarwal S, Ohlfest J, Elmquist W (2010) Evaluation of drug delivery to brain tumors: grind and find is not enough.18th international conference on brain tumor research and therapy, Tracemünde, Germany, pp 87-88
34. Fetterly GJ, Mita MM, Britten CD, Poplin E, Tap WD, Carmona A, Yonemoto L, Bedrosian CL, Rubin EH, Tolcher AW (2008) Pharmacokinetics of oral deforolimus (AP23573, MK-8669). J Clin Oncol 26; Abstr 14555
35. Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, Peralba JM, Jenkins RB, Dakhil SR, Morton RF, Jaeckle KA, Scheithauer BW, Dancey J, Hidalgo M, Walsh DJ (2005) Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central cancer treatment group study. J Clin Oncol 23(23):5294-5304 (Pubitemid 46206983)
36. Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, De Angelis L, Raizer J, Hess K, Aldape K, Lamborn KR, Kuhn J, Dancey J, Prados MD (2005) Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23(4):357-361 (Pubitemid 40980358)
37. Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Friedman AH, Herndon JE 2nd, Marcello J, Norfleet JA, McLendon RE, Sampson JH, Friedman HS (2010) Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol 96(2):219-230
38. Novartis drug Afinitor® met primary endpoint of Phase III study in women with advanced breast cancer; potential to address significant unmet need. http://www.novartis.com/newsroom/media-releases/en/2011/1528340.shtml. Accessed August 24, 2011